🔥 $ESPR 🕒 ср, 16 дек. 2020 г., 13:31:13 MSK Daiichi Sankyo, Esperion announce Swissmedic approval for LDL-C treatment Daiichi Sankyo and Esperion announced Swissmedic approval for Nilemdo tablet and Nustendi tablet, offering new treatment options for people with high low-density lipoprotein cholesterol, or LDL-C, in Switzerland. Bempedoic acid is the first oral, once-daily treatment option approved in the last two decades for patients who have difficulty reaching their cholesterol-lowering goals. In a recent observational study, two-thirds of patients in Switzerland with very high cardiovascular risk did not achieve LDL-C target values set out by the European Society of Cardiology. Patients who do not reach their LDL-C lowering goals are at increased risk for heart attack and stroke. Diagnosis of high cholesterol has increased among older adults in Switzerland in the past 20 years.